HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Progressive coccidioidomycosis — Clinical Guidelines

Overview

Progressive pseudorheumatoid dysplasia (PPRD) is a rare autosomal recessive disorder characterized by progressive degeneration of articular cartilage leading to significant joint stiffness, deformity, and disability without inflammation. Primarily affecting children between the ages of 3 and 8 years, it manifests through joint enlargement, limited range of motion, and skeletal deformities such as scoliosis and kyphosis. Given its non-inflammatory nature, PPRD is often misdiagnosed as juvenile idiopathic arthritis or spondyloarthritis, delaying appropriate management. Early recognition and intervention are crucial for mitigating long-term disability, making accurate diagnosis a key aspect of day-to-day clinical practice 1 2 3.

Pathophysiology

PPRD arises from mutations in the CCN6 (formerly WISP3) gene, which plays a critical role in skeletal growth and cartilage homeostasis. These genetic mutations disrupt normal cartilage metabolism, leading to progressive degeneration and loss of articular cartilage across multiple joints. The molecular dysfunction results in characteristic joint deformities, including finger joint and knee enlargement, and skeletal abnormalities such as platyspondyly and short stature. Over time, the lack of cartilage repair mechanisms exacerbates joint stiffness and pain, contributing to significant functional impairment 1 2 3 4.

Epidemiology

PPRD is exceedingly rare, with an estimated incidence of approximately 1 in 1,000,000 individuals 1. It predominantly affects children, typically presenting between the ages of 3 and 8 years, though onset can be delayed into adolescence as seen in some case reports 2 3 5. The condition appears to be uniformly distributed across genders and geographic regions, with no significant ethnic predisposition noted in the literature reviewed. Large cohort analyses are limited, particularly in diverse populations, highlighting the need for broader epidemiological studies to refine prevalence estimates and identify potential risk factors 3.

Clinical Presentation

The clinical presentation of PPRD is marked by progressive joint involvement starting with the interphalangeal joints, followed by larger joints like the knees, hips, and elbows. Common symptoms include joint swelling, stiffness, and limited range of motion, often accompanied by skeletal deformities such as scoliosis, kyphosis, and a short torso. Patients may also experience generalized movement limitations, gait abnormalities, and secondary complications like bone marrow edema, as reported in some cases 2 4 5. Early signs like persistent scoliosis in infancy, as noted in one case report, can be indicative but are not universally recognized 1.

Diagnosis

Diagnosing PPRD involves a comprehensive clinical evaluation combined with imaging and genetic testing. Key diagnostic criteria include:

Clinical Features: Progressive joint deformities, particularly in small joints progressing to larger joints, with characteristic radiographic findings.

Radiographic Findings: Joint space narrowing, osteophyte formation, platyspondyly, and characteristic skeletal changes.

Laboratory Tests: Normal inflammatory markers (ESR, CRP) to rule out inflammatory arthritis.

Genetic Testing: Identification of mutations in the CCN6 gene, with over 64 different mutations reported 1 2 3 4.

Differential Diagnosis:

Juvenile Idiopathic Arthritis (JIA): Distinguished by elevated inflammatory markers and presence of synovitis.

Spondyloarthropathies: Typically associated with inflammatory back pain and enthesitis.

Other Skeletal Dysplasias: Differentiated by specific genetic mutations and distinct radiographic patterns 1 3 4.

Management

Initial Management

Physical Therapy: Focus on maintaining joint mobility and muscle strength.

Pain Management: Use of analgesics (e.g., NSAIDs) for symptomatic relief, though efficacy may be limited due to non-inflammatory nature.

Orthotic Support: Braces or splints to support joint function and posture.

Advanced Management

Surgical Interventions: Considered in advanced cases for joint stabilization or correction of severe deformities (e.g., Ilizarov technique for limb lengthening or joint reconstruction).

Genetic Counseling: Essential for families to understand inheritance patterns and potential risks in offspring.

Specific Interventions:

Physical Therapy: Regular sessions focusing on joint mobility exercises.

Pain Control: Low-dose NSAIDs (e.g., ibuprofen 20 mg/kg/day in divided doses) [Evidence: Moderate]

Orthotics: Custom-fitted braces to manage joint deformities [Evidence: Expert opinion]

Surgical Referral: For severe joint contractures or deformities unresponsive to conservative management [Evidence: Expert opinion]

Complications

Joint Contractures: Progressive limitation of joint movement requiring surgical intervention.

Secondary Osteoarthritis: Due to cartilage degeneration, leading to chronic pain and functional impairment.

Bone Marrow Edema: Reported in some cases, indicating increased bone stress and potential for fractures [Evidence: Moderate]

Referral Indicators: Persistent pain, significant functional decline, or severe deformities warrant specialist orthopedic referral [Evidence: Expert opinion]

Prognosis & Follow-up

The prognosis for PPRD is generally poor due to the progressive nature of joint and skeletal involvement, though life expectancy is typically preserved. Prognostic indicators include early onset and severity of joint involvement. Regular follow-up every 6-12 months is recommended to monitor disease progression and manage complications effectively. Imaging studies and clinical assessments are crucial for tracking changes in joint status and skeletal deformities [Evidence: Expert opinion].

Special Populations

Pediatrics: Early recognition is vital to prevent irreversible joint damage. Regular monitoring and multidisciplinary care are essential.

Adolescents: Often present with advanced joint deformities requiring careful consideration of surgical interventions like joint reconstruction or external fixation techniques.

Genetic Counseling: Particularly important for families with a history of PPRD to understand genetic risks and inheritance patterns [Evidence: Expert opinion]

Key Recommendations

Genetic Testing: Confirm diagnosis through CCN6 gene mutation analysis [Evidence: Strong]

Radiographic Evaluation: Include characteristic skeletal changes in diagnostic workup [Evidence: Strong]

Monitor Inflammatory Markers: Rule out inflammatory arthritis by confirming normal ESR and CRP levels [Evidence: Moderate]

Multidisciplinary Care: Involve orthopedic specialists, physical therapists, and genetic counselors [Evidence: Expert opinion]

Early Physical Therapy: Initiate to maintain joint mobility and prevent contractures [Evidence: Moderate]

Pain Management: Use NSAIDs cautiously for symptomatic relief [Evidence: Moderate]

Surgical Referral: For severe deformities or joint contractures unresponsive to conservative treatment [Evidence: Expert opinion]

Regular Follow-up: Schedule every 6-12 months to monitor disease progression [Evidence: Expert opinion]

Genetic Counseling: Offer to families for understanding inheritance risks [Evidence: Expert opinion]

Consider Orthotic Support: Custom braces to manage joint deformities and improve function [Evidence: Expert opinion]

References

1 Janoud O, Chaer S, Shikha Y, Khalil B. Could scoliosis at the age of 7 months be a manifestation of progressive pseudorheumatoid dysplasia? A case report. Journal of medical case reports 2025. link 2 Li Y, Huang Z, Yan Y, Guo F, Wei G, Wang Y et al.. Progressive pseudorheumatoid dysplasia involving a novel CCN6 mutation: a case report. Frontiers in immunology 2024. link 3 Wang W, Gao SH, Wei M, Zhong LQ, Liu W, Jian S et al.. Unique mutation spectrum of progressive pseudorheumatoid dysplasia in the Chinese population: a retrospective genotype-phenotype analysis of 105 patients. World journal of pediatrics : WJP 2023. link 4 Shahi P, Sehgal A, Sudan A, Sehgal S. Delayed-onset progressive pseudorheumatoid dysplasia with secondary synovial chondromatosis. BMJ case reports 2020. link 5 Li Y, Zeng Y, Chen Z, Xin H, Li X. Progressive pseudorheumatoid dysplasia confirmed by whole-exon sequencing in a Chinese adult before corrective surgery. Journal of orthopaedic surgery and research 2019. link 6 Chen W, Mo S, Luo G, Wang Y, Deng X, Zhu J et al.. Progressive pseudorheumatoid dysplasia with new-found gene mutation of Wntl inducible signaling pathway protein 3. Pediatric rheumatology online journal 2018. link 7 Xiao K, Li T, Jiang Y, Li Z, Zhu Q, Wu Z et al.. Ilizarov technique in an adolescent patient with progressive pseudorheumatoid dysplasia: A case report. Medicine 2018. link 8 Rai E, Mahajan A, Kumar P, Angural A, Dhar MK, Razdan S et al.. Whole Exome Screening Identifies Novel and Recurrent WISP3 Mutations Causing Progressive Pseudorheumatoid Dysplasia in Jammu and Kashmir-India. Scientific reports 2016. link 9 Xu K, Li G, Niu Y, Wu Z, Zhang TJ, Zhang S et al.. First copy number variant in trans with single nucleotide variant in CCN6 causing progressive pseudorheumatoid dysplasia revealed by genome sequencing and deep phenotyping in monozygotic twins. American journal of medical genetics. Part A 2024. link 10 Lin LJ, Ge YM, Tian Y, Liu N, Luo XH, Xue YT et al.. Multi-scale mechanical investigation of articular cartilage suffered progressive pseudorheumatoid dysplasia. Clinical biomechanics (Bristol, Avon) 2020. link 11 Montané LS, Marín OR, Rivera-Pedroza CI, Vallespín E, Del Pozo Á, Heath KE. Early severe scoliosis in a patient with atypical progressive pseudorheumatoid dysplasia (PPD): Identification of two WISP3 mutations, one previously unreported. American journal of medical genetics. Part A 2016. link 12 Luo H, Shi C, Mao C, Jiang C, Bao D, Guo J et al.. A novel compound WISP3 mutation in a Chinese family with progressive pseudorheumatoid dysplasia. Gene 2015. link 13 Yu Y, Hu M, Xing X, Li F, Song Y, Luo Y et al.. Identification of a mutation in the WISP3 gene in three unrelated families with progressive pseudorheumatoid dysplasia. Molecular medicine reports 2015. link 14 Gao YS, Ding H, Zhang CQ. Total hip arthroplasty in a 17-year-old girl with progressive pseudorheumatoid dysplasia. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2013. link 15 Marik I, Marikova O, Zemkova D, Kuklik M, Kozlowski K. Dominantly inherited progressive pseudorheumatoid dysplasia with hypoplastic toes. Skeletal radiology 2004. link

Progressive coccidioidomycosis